BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

AirNexis Secures Global Rights To Phase 2 COPD Asset AN01 In $200 Million Series A Backed By Frazier And OrbiMed

AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group Company founded by Frazier Life Sciences, which led...

January 12, 2026 | News

Biocytogen And Acepodia Advance Dual Payload Bispecific ADC Strategy Through Option Based Licensing Pact

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), announced that the companies have entered int...

January 12, 2026 | News

Zai Lab Secures China Approval For AUGTYRO In NTRK Fusion Positive Solid Tumours

-Zai Lab Limited announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sND...

January 09, 2026 | News

Oxeia Targets First Ever Treatment For Persistent Concussion Symptoms After Strong Phase 2a Results

Biotech showed 85% patient improvement in Phase 2a trial—zero approved treatments exist for persistent concussion symptoms Oxeia Biopharmaceuticals ...

January 09, 2026 | News

Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal To Deepen Oral Inflammation Pipeline

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on ...

January 09, 2026 | News

Nuclera Secures First Commercial Sales In Asia With Landmark Installations In Taiwan

Installations at National Taiwan University and National Cheng Kung University expand Nuclera’s global footprint with first commercial sales in Asi...

January 08, 2026 | News

Sichuan Kelun Biotech Secures NMPA IND Approval For SKB105 Antibody Drug Conjugate In Advanced Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) appli...

January 07, 2026 | News

Shanghai Ark Biopharmaceutical Secures NMPA Approval For Azstarys ADHD Treatment In China

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that China's National Medical Products Administration (NMPA) has approved the New D...

January 07, 2026 | News

C&R Research Deepens Indonesia Engagement Through Global Clinical Trial Capabilities

Accelerating Indonesia Collaboration through Global Clinical Capabilities C&R Research, founded in 1997 as Korea's first full-service Contract R...

January 06, 2026 | News

ScinoPharm Taiwan Becomes First In Country To Secure US FDA Approval For Multiple Sclerosis Injection

ScinoPharm Taiwan announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Gl...

January 06, 2026 | News

CivicaScript Expands Affordable Biosimilar Access With Insulin And Ustekinumab Launches

CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines and biosimilars to U.S. patients, announced the availabi...

January 06, 2026 | News

Samsung Bioepis Takes Full Control Of BYOOVIZ Commercialisation In Europe

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ® BYOOVIZ becomes the fourth biosimila...

January 05, 2026 | News

INOVIO BLA For INO 3107 Accepted By FDA With Standard Review Timeline

INOVIO, a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer,...

January 02, 2026 | News

Sinopia Biosciences Secures NIH Grant To Advance Data Driven Drug Discovery Platform

-Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS® drug discovery platform, annou...

January 01, 2026 | News

Stay Connected